Overview

Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

Status:
Completed
Trial end date:
2002-03-27
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of troxacitabine in treating patients who have blast phase chronic myelogenous leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Shire
Treatments:
Troxacitabine